Abstract
Due to the molecular complexity of cancer, combination therapy is becoming increasingly important for better long-term prognosis with fewer side effects. To further increase the therapeutic effects, advanced drug delivery systems (DDSs), capable of simultaneously delivering multiple drugs to the site of action with specific time-programmed release profiles, are important requirements. Nanocarriers for the simultaneous co-delivery of multiple chemical drugs in combination therapy have been extensively reviewed. Here we focus on the nanotechnology enabled DDSs for the simultaneous co-delivery of therapeutic genes and chemical drugs for cancer treatment. The opportunities for this combination strategy and their challenges will be discussed.
Keywords: Cancer, co-delivery, drug delivery, liposomes, mesoporous silica nanoparticles, nanocarriers, siRNA.
Current Pharmaceutical Biotechnology
Title:Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
Volume: 13 Issue: 7
Author(s): Nazia N. Choudhury and Huixin He
Affiliation:
Keywords: Cancer, co-delivery, drug delivery, liposomes, mesoporous silica nanoparticles, nanocarriers, siRNA.
Abstract: Due to the molecular complexity of cancer, combination therapy is becoming increasingly important for better long-term prognosis with fewer side effects. To further increase the therapeutic effects, advanced drug delivery systems (DDSs), capable of simultaneously delivering multiple drugs to the site of action with specific time-programmed release profiles, are important requirements. Nanocarriers for the simultaneous co-delivery of multiple chemical drugs in combination therapy have been extensively reviewed. Here we focus on the nanotechnology enabled DDSs for the simultaneous co-delivery of therapeutic genes and chemical drugs for cancer treatment. The opportunities for this combination strategy and their challenges will be discussed.
Export Options
About this article
Cite this article as:
N. Choudhury Nazia and He Huixin, Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs, Current Pharmaceutical Biotechnology 2012; 13 (7) . https://dx.doi.org/10.2174/138920112800624418
DOI https://dx.doi.org/10.2174/138920112800624418 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index to Volume 3
Current Gene Therapy Bleomycin Induced Sensitivity to TRAIL/Apo-2L-Mediated Apoptosis in Human Seminomatous Testicular Cancer Cells is Correlated with Upregulation of Death Receptors
Anti-Cancer Agents in Medicinal Chemistry Modified cAMP Derivatives: Powerful Tools in Heart Research
Current Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Targeting Prostate Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Editorial [Hot Topic: Designing New Drugs For High Grade Gliomas (Executive Guest Editor: Guido Frosina)]
Current Pharmaceutical Design Combination of Salinomycin and AZD3463 Reveals Synergistic Effect on Reducing the Viability of T98G Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Nano-Carriers of Combination Tumor Physical Stimuli-Responsive Therapies
Current Drug Delivery Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry Peptides as Carrier for Tumor Diagnosis and Treatment
Current Medicinal Chemistry - Anti-Cancer Agents